Waters Corp
Change company Symbol lookup
Select an option...
WAT Waters Corp
ADP Automatic Data Processing Inc
CLABF Core One Labs Inc
FRHLF Freehold Royalties Ltd
WDAY Workday Inc
ENVX Enovix Corp
ENB Enbridge Inc
CHKP Check Point Software Technologies Ltd
NUSI Nationwide Nasdaq-100® Risk-Managed Income ETF
AMSF Amerisafe Inc
Go

Health Care : Life Sciences Tools & Services | Mid Cap Blend
Company profile

Waters Corporation is a specialty measurement company that primarily designs, manufactures, sells and services high performance liquid chromatography (HPLC) ultra-performance liquid chromatography and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. The Company’s segments include Waters and TA. The Waters operating segment is designing, manufacturing, selling and servicing liquid chromatography (LC) and MS instruments, columns and other precision chemistry consumables that can be integrated and used along with other analytical instruments. The TA operating segment is designing, manufacturing, selling and servicing thermal analysis, rheometry and calorimetry instruments. Its LC and LC-MS instruments are utilized in a range of industries to detect, identify, monitor and measure the chemical, physical and biological composition of materials, and to purify compounds.

Closing Price
$333.73
Day's Change
-4.21 (-1.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
337.90
Day's Low
329.53
Volume
(Light)
Volume:
285,221

10-day average volume:
421,364
285,221

FINAL DEADLINE: NOVEMBER 1, 2021 SPECTRUM PHARMACEUTICALS, INC. (NASDAQ: SPPI) CLASS ACTION LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.

1:56 pm ET October 29, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / October 29, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the November 1, 2021 deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ:SPPI) from December 27, 2018, through August 5, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the District of Nevada alleges violations of the Securities Act of 1934.

Image: https://www.accesswire.com/logos/thumbs/5184.jpg

If you purchased Spectrum securities, and/or would like to discuss your legal rights and options please visit Spectrum Shareholder Class Action Lawsuit or contact RujulPatel toll-free at (877) 779-1414 or rpatel@bernlieb.com

According to the complaint, Spectrum issued materially false and/or misleading statements and failed to disclose adverse facts pertaining to the quality and integrity of the scientific data supporting the company's claims of efficacy for its drug ROLONTIS (eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia, which was known to, or recklessly disregarded by, the Defendants as follows: (a) the ROLONTIS manufacturing facility maintained deficient controls and/or procedures; (b) the foregoing deficiencies decreased the likelihood that the U.S. Food and Drug Administration ("FDA") would approve the ROLONTIS Biologics License Application ("BLA") as submitted in December 2018 in its current form; (c) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (D) as a result, the Company's public statements were materially false and misleading at all relevant times.

On August 6, 2021, Spectrum announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the ROLONTIS BLA. The CRL cited deficiencies related to manufacturing and indicated that a reinspection of the Company's manufacturing facility will be necessary.

On this news, the price of Spectrum shares fell $0.70 per share, or 21.54%, to close at $2.55 per share on August 6, 2021.

If you wish to serve as lead plaintiff, you must move the Court no later than November 1, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased Spectrum securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/spectrumpharmaceuticalsinc-sppi-shareholder-class-action-lawsuit-fraud-stock-437/apply/ or contact Rujul Patel toll-free at (877) 779-1414 or rpatel@bernlieb.com

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Rujul Patel

Bernstein Liebhard LLP

https://www.bernlieb.com

(877) 779-1414

rpatel@bernlieb.com

SOURCE: Bernstein Liebhard LLP

View source version on accesswire.com:

https://www.accesswire.com/670376/FINAL-DEADLINE-NOVEMBER-1-2021-SPECTRUM-PHARMACEUTICALS-INC-NASDAQ-SPPI-CLASS-ACTION-LAWSUIT-DEADLINE-Bernstein-Liebhard-LLP-Reminds-Investors-of-the-Deadline-to-File-a-Lead-Plaintiff-Motion-in-a-Securities-Class-Action-Lawsuit-Against-Spectrum

comtex tracking

COMTEX_396059930/2457/2021-10-29T13:56:56

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.